Current biochemical monitoring and risk management of immunosuppressive therapy after transplantation
| Autor: | Catić-Đorđević Aleksandra, Cvetković Tatjana, Stefanović Nikola, Veličković-Radovanović Radmila |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Journal of Medical Biochemistry, Vol 36, Iss 1, Pp 1-7 (2017) |
| Druh dokumentu: | article |
| ISSN: | 1452-8258 1452-8266 |
| Popis: | Immunosuppressive drugs play a crucial role in the inhibition of immune reaction and prevention of graft rejection as well as in the pharmacotherapy of autoimmune disorders. Effective immunosuppression should provide an adequate safety profile and improve treatment outcomes and the patients' quality of life. High-risk transplant recipients may be identified, but a definitive prediction model has still not been recognized. Therapeutic drug monitoring (TDM) for immunosuppressive drugs is an essential, but at the same time insufficient tool due to low predictability of drug exposition and marked pharmacokinetic variability. Parallel therapeutic, biochemical and clinical monitoring may successfully optimize and individualize therapy for transplanted recipients, providing optimal medical outcomes. Modern pharmacotherapy management should include new biomarkers with better sensitivity and specificity that can identify early cell damage. The aim of this study was to point out the importance of finding new biomarkers that would enable early detection of adverse drug events and cell damage in organ transplant recipients. We wanted to confirm the importance of routine biochemical monitoring in improving the safety of immunosuppressive treatment. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|